We focused our attention on the EGFR gene for NSCLC samples, KRAS, and BRAF genes for mCRC samples, and the BRAF gene for melanoma samples, because target therapy for the mutation of these genes can be prescribed by clinicians. The gene discussed is BRAF; the disease is melanoma.